Evidence map›Paper›PMID 41769279›Full record

ArticleArchives of Razi Institute2025

Effectiveness of COVID-19 Vaccines in Mahabad, Iran: A Cohort Study.

Parsa Nasrin, Salarilak Shaker, Heidari Mohammad

Abstract read
In one paragraph

Article in Archives of Razi Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Parsa NasrinDepartment of Epidemiology and Biostatistics, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Salarilak ShakerDepartment of Epidemiology and Biostatistics, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Heidari MohammadDepartment of Epidemiology and Biostatistics, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic has demonstrated the seriousness of infectious diseases , underscoring the critical role of vaccination in preventing such outbreaks. The aim of study was to examine the effectiveness of the vaccines against COVID-19 in city of Mahabad in the northwestern region of Iran. This retrospective cohort study compared 1077 vaccinated employees of the Mahabad city health department ( the exposed group) with 1338 unvaccinated employees from other departments (the unexposed group). Demographic details, vaccination dates, types, and outcomes were extracted from the local health system. Data on cases came from the disease unit, and hospitalization came from the Medical Care Monitoring Center (MCMC). Attributable fractions for the exposed group and relative risks with 95% confidence intervals were calculated for each vaccine dose, stratified by sex, age group, and exposure level. Data analysis was conducted using STATA16, with a p-value < 0.05 was considered statistically significant. The overall efficacy of COVID-19 vaccines in preventing the disease is 51%, with 26% effectiveness in preventing hospitalization. When stratified by vaccine type, AstraZeneca exhibits an 81% efficacy (95% CI: 0.61-0.91) in preventing infection. This is followed by Sputnik at 41% efficacy (95% CI: 0.086-0.62) and Sinopharm-Baharat at 10% efficacy (95% CI: 0.50-0.46). Similarly, AstraZeneca demonstrates a 79% efficacy (95% CI: 0.083-0.95), Sputnik demonstrates 29% efficacy (95% CI: 0.77-0.71), and Sinopharm-Bharat at 44% efficacy (95% CI: 0.63-0.81) in preventing hopitalization. Notably the efficacy of preventing both disease and hospitalization is higher in men than women. The AstraZeneca vaccine is the most effective at preventing both disease and hospitalization, followed by Sputnik. Analyzing vaccine effectiveness across age groups reveals the lowest efficacy in individuals below 30 years old, and the highest efficacy individuals above 51 years. Despite challenges of selecting and administering vaccines in a timely manner in Iran, our findings demonstrate that three doses of COVID-19 vaccines are over 75% effective at preventing hospitalization and death, underscoring the vital role of vaccination as a primary preventive measure against infectious disease outbreaks. These results highlight the importance of proactive preparation and investment in robust vaccination programs for effective epidemic control.

Indexed as

COVID-19COVID-19 VaccinesSARS-CoV-2Vaccine EfficacyAdultCohort StudiesFemaleHospitalizationHumansIranMaleMiddle AgedRetrospective StudiesUnvaccinated PersonsVaccinationYoung AdultCOVID-19 VaccinesCOVID-19 VaccinesIranRisk AssessmentRisk RatioVaccine Efficacy

Identifiers

PMID41769279
PMCPMC12936618

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.